Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Commentary|Articles|June 16, 2026
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
Author(s)Caroline Seymour, Ashling Wahner
Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the
Related to this article
Niraparib/Dostarlimab Plus CRT Displays Efficacy but Has Toxicity Concerns in Locally Advanced HNSCC
Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.
Updated FONTANA data show torvu-sam activity across FRα expression levels in platinum-resistant ovarian cancer.
In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.
Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.
Divarasib extended survival over first-generation KRAS G12C inhibitors in a head-to-head phase 3 trial in previously treated lung cancer.
In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.
Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Advertisement
Advertisement